SCHEMBL577856

SCHEMBL577856

Fc1cccc(F)c1I

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8985713 0.84
SCHEMBL1768320 0.80
SCHEMBL29533880 0.80
SCHEMBL30702028 0.80
SCHEMBL5979692 0.80
SCHEMBL2883006 0.80
SCHEMBL1964436 0.80
SCHEMBL512894 0.80
SCHEMBL943340 0.78 APOBEC3G (0.39)
Hydrochloric Acid SCHEMBL1963775 0.78 CYP3A4 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115246858-A Phosphine-oxa bidentate ligand and its coordinated transition metal complex and use 东莞市均成高新材料有限公司 2022-10-28 CN claimed
EP-1362860-B1 Method for producing tetrakis (fluoraryl)borate magnesium compound NIPPON CATALYTIC CHEM IND (JP) 2010-09-15 EP claimed
US-7205441-B2 Method for producing tetrakis (fluoroaryl) borate-magnesium compound NIPPON SHOKUBAI CO., LTD. (JP) 2007-04-17 US claimed
US-20030216598-A1 Method for producing tetrakis ( fluoroaryl) borate-magnesium compound NIPPON SHOKUBAI CO., LTD. (JP) 2003-11-20 US claimed
EP-1362860-A1 Method for producing tetrakis (fluoroaryl) borate magnesium compound Nippon Shokubai Co., Ltd. (JP) 2003-11-19 EP claimed
WO-2026086794-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF THE CHINESE UNIVERSITY OF HONG KONG (CN) 2026-04-30 WO disclosed
US-20260116891-A1 Oxazepin Derivative TEIJIN PHARMA LTD (JP) 2026-04-30 US disclosed
EP-4731634-A1 SMALL-MOLECULE STABILIZERS OF THE CHREBP 14-3-3 INTERACTION Technische Universiteit Eindhoven (NL) 2026-04-29 EP disclosed
US-12552771-B2 Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases CELGENE CORPORATION (US) 2026-02-17 US disclosed
EP-4688785-A1 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 Beone Medicines I GmbH (CH) 2026-02-11 EP disclosed
US-20260022094-A1 Compounds for the Treatment of Neurodegenerative Diseases CELGENE CORPORATION (US) 2026-01-22 US disclosed
US-20260022130-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2026-01-22 US disclosed
US-20020072525-A1 Aryl fused azapolycyclic compounds PFIZER INC 2002-06-13 US disclosed
WO-2001062736-A1 ARYL FUSED AZAPOLYCYCLIC COMPOUNDS PFIZER PRODUCTS INC. (US) 2001-08-30 WO disclosed
CN-1285821-A Aryl Fused azapolycyclic compounds PFIZER PROD INC (US) 2001-02-28 CN disclosed
EP-1044189-A1 ARYL FUSED AZAPOLYCYCLIC COMPOUNDS Pfizer Products Inc. (US) 2000-10-18 EP disclosed
WO-1999035131-A1 ARYL FUSED AZAPOLYCYCLIC COMPOUNDS PFIZER PRODUCTS INC. (US) 1999-07-15 WO disclosed
EP-0109606-B1 PROCESS FOR THE FORMYLATION OF ARYL HALIDES BAYER AG (DE) 1986-01-22 EP disclosed
US-4536344-A USING A PHOSPINE OR PHOSPHITE BAYER AKTIENGESELLSCHAFT (DE) 1985-08-20 US disclosed
EP-0109606-A1 Process for the formylation of aryl halides BAYER AG (DE) 1984-05-30 EP disclosed